Company: NCEL
Filing Date: 2025-08-06
Form Type: 6-K
Source: 0001213900-25-072320
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-08-06
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2025

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

Warrant Exchange Agreement

On
August 5, 2025, NLS Pharmaceutics Ltd. (the “Company”) entered into a warrant exchange agreement (the “Exchange Agreement”)
with Alpha Capital Anstalt (the “Holder”). Pursuant to the terms of the Exchange Agreement, the Company and the Holder agreed
to exchange a certain common share purchase warrant dated October 10, 2024 to purchase 207,913 of the Company’s common shares previously
issued to the Holder under a securities purchase agreement dated October 9, 2024, between the Company and certain accredited investors,
including the Holder (the “Warrant”), for 100,000 common shares, par value CHF 0.03 of the Company (the “Exchange Shares”).

The
Exchange Shares are being issued in reliance on an exemption from registration under Section 3(a)(9) of the Securities Act of 1933, as
amended. Pursuant to the Exchange Agreement, the Company agreed to issue the Exchange Shares within one trading day of execution, and
acknowledged that the Holder’s holding period for Rule 144 purposes will tack back to the original issue date of the Warrant. The
Exchange Shares will have the same rights as the warrant shares under specified provisions of the Warrant.

In
addition, the Holder waived any liquidated damages related solely to the Company’s registration obligations under the Securities
Purchase Agreements dated October 9, 2024 and December 4, 2024, and the related Registration Rights Agreement, all as previously executed
between the Company and the Holder. No other rights under any other